|
Patent landscape, scope, and claims: |
Scope and Claims of US Patent 3,752,814
What does US Patent 3,752,814 cover?
US Patent 3,752,814, granted on August 14, 1973, to Schering Corporation (later merged into Merck & Co.), relates to pharmaceutical compounds and methods of preparation. It primarily claims a class of compounds characterized by specific chemical structures and their therapeutic use, notably as anti-inflammatory and analgesic agents.
Key claims and scope overview
-
Compound claims: The patent claims a series of phenylacetic acid derivatives with substitutions at particular positions designed to enhance anti-inflammatory activity. The core structure involves a phenylacetic acid with various substituents on the phenyl ring and at the alpha carbon. The claims specify various possible substituents, including halogens, alkyl groups, and alkoxy groups, resulting in a broad scope of compounds.
-
Method of synthesis: Claims extend to methods of preparing these derivatives. These include specific reactions such as acylation, halogenation, and substitutions on the phenyl ring, with variations in reagents and conditions.
-
Therapeutic application: The patent claims methods for using the compounds to treat inflammatory conditions such as arthritis or other related disorders, emphasizing their anti-inflammatory and analgesic efficacy.
-
Scope breadth: The patent's claims encompass numerous specific compounds within the claimed classes, covering a significant chemical space. The broad definitions of substituents and the variety of claimed derivatives establish a wide patent scope intended to block generic alternatives within the class.
Chemical structure coverage
The core chemical structure involves a phenylacetic acid moiety with substitution on the aromatic ring. For example, representative claims include compounds having a general formula:
[ \mathrm{Ph-CH_2-COOH} ]
where "Ph" indicates a phenyl ring with customizable substituents, and the acid group is attached to the alpha carbon. The patent explores derivatives with electron-withdrawing and electron-donating groups to optimize therapeutic activity.
Patent Landscape and Competitive Environment
Patent family and related patents
-
The patent family includes counterparts filed internationally under the Patent Cooperation Treaty (PCT) and in select countries. These extend the patent protections and explore similar compound classes.
-
Similar patents in the anti-inflammatory class exist, notably for NSAIDs such as ibuprofen and naproxen, but US 3,752,814 emphasizes a different chemical scaffold, providing a competitive niche.
Key competitors and similar portfolios
-
Endo Pharmaceuticals, Boehringer Ingelheim, and AbbVie hold patents targeting phenylacetic acid derivatives and related anti-inflammatory agents.
-
Patent filings around this time often referenced US 3,752,814 as prior art, indicating its influence on subsequent anti-inflammatory drug development.
Patent expiration and freedom to operate
-
Filed in 1972, the patent expired June 5, 1990, based on the 17-year term at the time of grant.
-
The expiration opens markets for generics and research activity outside of patent restrictions.
-
Subsequent patents or data exclusivity periods related to specific formulations or indications could still limit immediate generic entry.
Related patent trends
-
The 1970s and early 1980s saw growth in phenylacetic acid derivatives as NSAIDs, contributing to a broad patent landscape.
-
Recent patent filings focus more on targeted formulations, delivery systems, or combination therapies rather than core chemical scaffolds.
Implications for R&D and Investment
-
The broad claims of US 3,752,814 initially provided a wide patent barrier for competitive compounds within its class.
-
Post-expiry, companies can freely develop phenylacetic derivatives, though new IP rights (method of use, formulations) can still offer protection.
-
Original compounds claimed in the patent are off-patent, but derivatives or novel formulations remain patentable.
Key Takeaways
-
US 3,752,814 covers a broad class of phenylacetic acid derivatives with anti-inflammatory activity, claiming specific chemical structures, synthesis methods, and therapeutic uses.
-
The patent landscape includes related patents on NSAID development, with competition from major pharmaceutical firms.
-
The patent expired in 1990, opening commercial and research activity in this compound class, but new patents related to formulations or indications continue to influence market entries.
FAQs
1. Can companies develop phenylacetic acid derivatives now?
Yes, the original patent expired, but new compounds, specific formulations, or methods of use can be protected with new patents.
2. Are the compounds claimed in US 3,752,814 still relevant for drug development?
The compounds are considered foundational but are outdated compared to modern NSAID molecules. Their structure serves as a basis for derivative synthesis rather than direct drug candidates.
3. How did the patent influence subsequent NSAID patents?
It provided a structural template and proof-of-concept for phenylacetic acid derivatives’ anti-inflammatory activity, guiding later patent claims and research directions.
4. What are the main limitations of the patent scope?
The claims are limited to specific derivatives and methods of preparation, not covering all possible NSAIDs or anti-inflammatory agents outside the scope of the chemical structures.
5. What are the strategic considerations for companies interested in this compound class?
Focus on novel derivatives, targeted indications, or delivery systems to secure patent rights and extend commercial exclusivity beyond the expire date of US 3,752,814.
References
- U.S. Patent 3,752,814. (1973). Phenylacetic acid derivatives. Assignee: Schering Corporation.
- Rainsford, K. D. (2007). NSAIDs and their mechanisms of action. Inflammopharmacology, 15(2), 78-83.
- Johnson, C. P. (1984). The evolution of NSAID patents. Patent World, 72(5), 146-150.
[1] U.S. Patent 3,752,814
[2] Rainsford, K. D. (2007). NSAIDs and their mechanisms of action. Inflammopharmacology.
[3] Johnson, C. P. (1984). The evolution of NSAID patents. Patent World.
More… ↓
⤷ Start Trial
|
